focus -WSS

focus

author：entertainment 2025-09-03 03:43:14 - browse：775

intarcia implant. -- health tech coverage from STAT — The matchstick-sized, implantable device from Intarcia Therapeutics releases a steady, continuous, and low-dose stream of a drug for diabetes. Stuart Isett/Fortune Brainstorm Health

An advisory panel to the Food and Drug Administration unanimously voted against a diabetes implant from Intarcia Therapeutics — a former biotech unicorn that faltered after the FDA rejected said implant not once, but twice.

Intarcia called for the panel meeting because of those two rejections, seeking outside input on the FDA’s decision. FDA then granted Intarcia’s request. The agency is not bound to advisory panel decisions, though it tends to follow their advice.

Intarcia started developing its lead therapy, a small, skinny bar implanted under the skin, for type 2 diabetes patients in 2016. The implant delivers a glucose-controlling medicine called exenatide, a member of the GLP-1 drugs that have taken the diabetes and obesity markets by storm. Intarcia’s implant continuously administers the drug over six months, with the goal of improving patient adherence compared to Eli Lilly and Novo Nordisk’s weekly GLP-1 shots.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： Beyond aggravation: Constipation is an American epidemic

focus

WSS

Hospitals need to get ahead of regulations on climate change

Protect nursing home residents from future pandemics

Elevance PBM president out as customers face prescription chaos

The world needs the new pandemic treaty

Fight over Supreme Court dialysis ruling puts kidney patients at risk

Richard Slayman had a rejection episode of his pig kidney before leaving hospital

hotspot

focus

entertainment

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Eli Lilly’s Zepbound improved liver scarring in mid

The cancer drug shortage isn’t new — and neither are the solutions

The Bio Revolution is changing business and society

Virginia high school admissions case could be legal follow

Anthony Fauci pushes back on GOP claims during Covid hearing

Bright Health sells Medicare Advantage business to Molina

A new initiative will help leaders fight the next pandemic

Continuity nursing helped my family in our darkest PICU moments

'Little Tech' descents on D.C., wanting a say in how AI is regulated

hotspot

A new initiative will help leaders fight the next pandemic

Richard Slayman had a rejection episode of his pig kidney before leaving hospital

Stroke rates rising, especially in working

Congress needs to close a vaccine

Why we need mandatory labeling of GMO products

Bird flu makes raw milk dangerous to consume, mouse study finds

focus

Wikipedia

focus

hotspot